Malignant Pleural Effusions. A Review.

Clinics in Chest Medicine

Volumn 34, Issue 3, 2013, Pages 459-471

  Thomas, Justin M ^a   Musani, Ali I ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

End stage malignancies; Malignant pleural effusions; Management; Review

Indexed keywords

ALPHA2B INTERFERON; BETA INTERFERON; CARBOPLATIN; CISPLATIN; CYTARABINE; DEOXYRIBONUCLEASE; DOCETAXEL; ETOPOSIDE; FIBRINOLYTIC AGENT; FLUOROURACIL; PACLITAXEL; SCLEROSING AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADVANCED CANCER; ALGORITHM; CANCER GENE THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CATHETER; CHEST TUBE PLEURODESIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECORTICATION; DISEASE COURSE; EMPYEMA; FINANCIAL MANAGEMENT; FUNCTIONAL STATUS; HEALTH CARE COST; HOSPITAL CARE; HOSPITALIZATION; HUMAN; INVASIVE PROCEDURE; LENGTH OF STAY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL TECHNOLOGY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PERITONEUM PLEURA SHUNT; PLEURA BIOPSY; PLEURA EFFUSION; PLEURECTOMY; PLEURODESIS; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT; SURGICAL APPROACH; SURGICAL DRAINAGE; SURGICAL TECHNIQUE; SYMPTOM; THORACOCENTESIS; THORACOSCOPIC PLEURODESIS; THORACOSCOPY; TREATMENT FAILURE; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY;

END-STAGE MALIGNANCIES; MALIGNANT PLEURAL EFFUSIONS; MANAGEMENT; REVIEW;

DRAINAGE; GENETIC THERAPY; GLAUCOMA DRAINAGE IMPLANTS; HUMANS; INCIDENCE; PARACENTESIS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; THORACOSCOPY;

EID: 84883049482     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.05.004     Document Type: Review

References (104)

1. Ruckdeschel J.C. Management of malignant pleural effusions. Semin Oncol 1994, 22:58-63.
2. Light R.W. Pleural diseases 2007, Lippincott, Williams & Wilkins, Baltimore (MD). 5th edition.
3. Antony V.B., Loddenkemper R., Astoul P., et al. Management of malignant pleural effusions. Eur Respir J 2001, 18:402-419.
4. Rodriguez-Panadero F., Naranjo F.B., Lopez-Mejias J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989, 2:366-369.
5. Marel M., Zrustova M., Stasny B., et al. The incidence of pleural effusion in a well-defined region: epidemiologic study in central Bohemia. Chest 1993, 104:1486-1489.
6. Valdes L., Alvarez D., Valle J.M., et al. The etiology of pleural effusions in an area with high incidence of tuberculosis. Chest 1996, 109:158-162.
7. Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5255 samples from 3811 patients. Diagn Cytopathol 1987, 3:8-12.
8. Sears D., Hajdu S.I. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987, 31:85-97.
9. Johnston W.W. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985, 56:905-909.
10. Chernow B., Sahn S.A. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977, 63:695-702.
11. Salyer W.R., Eggleston J.C., Erozan Y.S. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975, 67:536-539.
12. Antunes G., Neville E., Duffy J., et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003, 58:ii29-ii38.
13. Musani A.I. Treatment options for malignant pleural effusion. Curr Opin Pulm Med 2009, 15:380-387.
14. Meyer P.C. Metastatic carcinoma of the pleura. Thorax 1966, 21:437-443.
15. Light R.W., Hamm H. Malignant pleural effusion: would the real cause please stand up?. Eur Respir J 1997, 10:1701-1702.
16. Ashchi M., Golish J., Eng P., et al. Transudative malignant pleural effusions: prevalence and mechanisms. South Med J 1998, 91:23-26.
17. Hsia D., Musani A. Management of malignant pleural effusions. Curr Respir Care Rep 1983, 1:73-81.
18. Fentiman I., Reubens R.D., Hayward J.L. Control of pleural effusions in patients with breast cancer. A randomized trial. Cancer 1983, 2:737-739.
19. Tremblay A., Michaud G. Single-center experience with 250 tunneled pleural catheter insertions for malignant pleural effusions. Chest 2006, 129:362-368.
20. Qian Q., Zhan P., Sun W.K., et al. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma 2012, 59:433-439.
21. Kraft A., Weindel K., Ochs A., et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85:178-187.
22. Hott J.W., Yu L., Antony V.B., et al. Role of vascular endothelial growth factor (VEGF) in the formation of malignant pleural effusions. Am J Respir Crit Care Med 1999, 159:A212.
23. Martinez-Moragon E., Aparicio J., Sanchis J., et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998, 65:108-113.
24. Rodriguez-Panadero F., Montes-Worboys A. Mechanisms of pleurodesis. Respiration 2012, 83:91-98.
25. Teixeira L.R., Vargas F.S., Acencio M.M., et al. Influence of anti-inflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. Chest 2005, 128:4041-4045.
26. Teixeira L.R., Wu W., Chang D.S., et al. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest 2002, 121:216-219.
27. Xie C., Teixeira L.R., McGovern J.P., et al. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998, 157:1441-1444.
28. Heffner J.E., Nietert P.J., Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000, 117:87-95.
29. Tassi G.F., Davies R.J., Noppen M. Advanced techniques in medical thoracoscopy. Eur Respir J 2006, 28:1051-1059.
30. Lee P., Mathur P.N., Colt H.G. Advances in thoracoscopy: 100 years since Jacobaeus. Respiration 2010, 79:177-186.
31. Menzies R., Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991, 114:271-276.
32. Colt H.G. Thoracoscopy. A prospective study of safety and outcome. Chest 1995, 108:324-329.
33. Tan C., Sedrakyan A., Browne J., et al. The evidence on the effectiveness of management of malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006, 29:829-838.
34. Nakas A., Trousse D.S., Martin-Ucar A.E., et al. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008, 34:886-891.
35. Maziak D.E., Gagliardi A., Haynes A.E., et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005, 48:157-169.
36. Treasure T., Lang-Lazdunski L., Waller D., et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011, 12:763-772.
37. Zahid I., Routledge T., Bille A., et al. What is the best treatment for malignant pleural effusions?. Interact Cardiovasc Thorac Surg 2011, 12:818-823.
38. Lee Y., Baumann M.H., Maskell N.A., et al. Pleurodesis practice for malignant pleural effusion in five English-speaking countries: survey of pulmonologists. Chest 2003, 124:2229-2238.
39. Dresler C.M., Olak J., Herndon J.E., et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005, 127:909-915.
40. Rehse D.H., Aye R.W., Florence M.G. Respiratory failure following talc pleurodesis. Am J Surg 1999, 177:437-440.
41. Janssen J.P., Collier G., Astoul P., et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007, 369:1535-1539.
42. Ferrer J., Villarino M.A., Tura J.M., et al. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001, 119(6):1901-1905.
43. Davies H., Lee Y.C., Davies R.J. Pleurodesis for malignant pleural effusion: talc, toxicity and where next?. Thorax 2008, 63:572-574.
44. American Thoracic Society Management of malignant pleural effusions. Am J Respir Crit Care Med 2000, 162:1987-2001.
45. Janssen J. Pleurodesis. Principles and practice of interventional pulmonology 2012, 623-630. Springer, New York. A. Ernst, F.J. Herth (Eds.).
46. Roberts M.E., Neville E., Berrisford R.G., et al. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010, 65(Suppl 2):ii32-ii40.
47. Shaw P., Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004, (1). CD002916.
48. de Campos J.R., Vargas F.S., de Campos Werebe E., et al. Thoracoscopy talc poudrage: a 15-year experience. Chest 2001, 119:801-806.
49. Aelony Y., King R.R., Boutin C. Malignant pleura effusions: effective pleurodesis despite low pleural pH. Chest 1998, 113:1007-1012.
50. Zhang W., Wang G.F., Zhang H., et al. Medical thoracoscopic talc pleurodesis for malignant pleural effusion: an analysis of 27 cases. Beijing Da Xue Xue Bao 2008, 40:600-602.
51. Thompson R.L., Yau J.C., Donnelly R.F., et al. Pleurodesis with iodized talc for malignant effusions using pigtail catheters. Ann Pharmacother 1998, 32:739-742.
52. Marom E.M., Patz E.F., Erasmus J.J., et al. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology 1999, 210:277-281.
53. Dryzer S.R., Allen M.L., Strange C., et al. Acomparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993, 104:1763-1769.
54. Mager H.J., Maesen B., Verzijlbergen F., et al. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer 2002, 36:77-81.
55. Clementsen P., Evald T., Grode G., et al. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. Respir Med 1998, 92:593-596.
56. Spiegler P.A., Hurewitz A.N., Groth M.L. Rapid pleurodesis for malignant pleural effusions. Chest 2003, 23:1895-1898.
57. Parulekar W., Di Primio G., Matzinger F., et al. Use of small-bore vs. large-bore hest tubes for treatment of malignant pleural effusions. Chest 2001, 120(1):19-25.
58. Caglayan B., Torun E., Turan D., et al. Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large bore chest tube. Ann Surg Oncol 2008, 15(9):2594-2599.
59. Mañes N., Rodriguez-Panadero F., Bravo J.L., et al. Talc pleurodesis: prospective and randomized study. Clinical follow-up. Chest 2000, 118:131S.
60. Rahman N.M., Maskell N.A., West A., et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. NEngl J Med 2011, 365:518-526.
61. Hsu L.H., Soong T.C., Feng A.C., et al. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. JThorac Oncol 2006, 1:460-467.
62. Gilkeson R.C., Silverman P., Haaga J.R. Using urokinase to treat malignant pleural effusions. AJR Am J Roentgenol 1999, 173:781-783.
63. Davies C.W., Traill Z.C., Gleeson F.V., et al. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest 1999, 115:729-733.
64. Okur E., Baysungur V., Tezel C., et al. Streptokinase for malignant pleural effusions: a randomized controlled study. Asian Cardiovasc Thorac Ann 2011, 19:238-243.
65. Hausheer F.H., Yarbro J.W. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985, 12:54-75.
66. Adler R.H., Sayek I. Treatment of malignant pleural effusion: a method using tube thoracostomy and talc. Ann Thorac Surg 1976, 22:8-15.
67. Villanueva A.G., Gray A.W., Shahian D.M., et al. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994, 49:23-25.
68. Echevarria C., Twomey D., Dunning J., et al. Does reexpansion pulmonary oedema exist?. Interact Cardiovasc Thorac Surg 2008, 7:485-489.
69. Sherman S.C. Reexpansion pulmonary edema: a case report and a review of the current literature. JEmerg Med 2003, 24:23-27.
70. Feller-Kopman D., Berkowitz D., Boiselle P., et al. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007, 84:1656-1661.
71. Mahfood S., Hix W.R., Aaron B.L., et al. Reexpansion pulmonary edema. JThorac Imaging 1988, 45:340-345.
72. Tarver R.D., Broderick L.S., Conces D.J. Reexpansion pulmonary edema. JThorac Imaging 1996, 11:198-209.
73. Feller-Kopman D., Walkey A., Berkowitz D., et al. The relationship of pleural pressure to symptom development during therapeutic thoracentesis. Chest 2006, 129:1556-1560.
74. Stretton F., Edmonds P., Marrinan M. Malignant pleural effusions. Eur J Palliat Care 1999, 6:5-9.
75. Putnam J.B., Light R.W., Rodriguez R.M., et al. Arandomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999, 86:1992-1999.
76. Warren W.H., Kalimi R., Khodadadian L.M., et al. Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg 2008, 85:1049-1050.
77. Van Meter M.E., McKee K.Y., Kohlwes R.J. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. JGen Intern Med 2011, 26:70-76.
78. Fysh E.T., Waterer G.W., Kendall P., et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012, 142:394-400.
79. Davies H.E., Mishra E.K., Kahan B.C., et al. Effect of an indwelling pleural catheter vs. chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion the TIME2 randomized controlled trial. JAMA 2012, 307:2383-2389.
80. Reich H., Beattie E.J., Harvey J.C. Pleuroperitoneal shunt for malignant pleural effusions: a one-year experience. Semin Surg Oncol 1993, 9:160-162.
81. Lee K.A., Harvey J.C., Reich H., et al. Management of malignant pleural effusions with pleuroperitoneal shunting. JAm Coll Surg 1994, 178:586-588.
82. Genc O., Petrou M., Ladas G., et al. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000, 18:143-146.
83. Tsang V., Fernando H.C., Goldstraw P. Pleuroperitoneal shunt for recurrent malignant pleural effusions. Thorax 1990, 45:369-372.
84. Schulze M., Boehle A.S., Kurdow R., et al. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001, 71:1809-1812.
85. Puri V., Pyrdeck T.L., Crabtree T.D., et al. Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg 2012, 94:374-380.
86. Reddy C., Ernst A., Lamb C., et al. Rapid pleurodesis for malignant pleural effusions. Chest 2011, 139:1419-1423.
87. Tohda Y., Iwanaga T., Takada M., et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999, 45:197-204.
88. Seto T., Ushijima S., Yamamoto H., et al. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 2006, 95:717-721.
89. Shoji T., Tanaka F., Yanagihara K., et al. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest 2002, 121:821-824.
90. Su W.C., Lai W.W., Chen H.H., et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion: a pilot study. Oncology 2003, 64:18-24.
91. Matsuzaki Y., Edagawa M., Shimizu T., et al. Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis. Ann Thorac Surg 2004, 78:1769-1772.
92. Lombardi G., Nicoletto M.O., Gusella M., et al. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol 2012, 69:781-787.
93. Perng R.P., Chen Y.M., Wu M.F., et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med 1998, 92:473-479.
94. Jones D.R., Taylor M.D., Petroni G.R., et al. Phase I trial of intrapleural docetaxel through an implantable catheter in subjects with a malignant pleural effusion. JThorac Oncol 2010, 5:75-78.
95. Lerza R., Vannozzi M.O., Tolino G., et al. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol 1997, 8(4):385-391.
96. Ichinose Y., Tsuchiya R., Koike T. Aprematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. JThorac Cardiovasc Surg 2002, 123:695-699.
97. Chen W.J., Yuan S.F., Yan Q.Y., et al. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study. Cancer Invest 2012, 30:126-130.
98. Zarogoulidis P., Chatzaki E., Hohenforst-Schmidt W., et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. Cancer Gene Ther 2012, 19:593-600.
99. Sterman D.H., Recio A., Carroll R.G., et al. Aphase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007, 13:4456-4466.
100. Sterman D.H., Haas A., Moon E., et al. Atrial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011, 184:1395-1399.
101. Zhao W.Z., Wang J.K., Li W., et al. Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer. Ai Zheng 2009, 28:1324-1327.
102. Dong M., Li X., Hong L.J., et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. JInt Med Res 2008, 36:1273-1278.
103. Haas A., Sterman D.H. Novel intrapleural therapies for malignant diseases. Respiration 2012, 83:277-292.
104. Kriegel I., Daniel C., Falcou M.C., et al. Use of a subcutaneous implantable pleural port in the management of recurrent malignant pleurisy: five-year experience based on 168 subcutaneous implantable pleural ports. JPalliat Med 2011, 14:829-834.